- Previous Close
6,690.00 - Open
6,550.00 - Bid 6,700.00 x --
- Ask 6,690.00 x --
- Day's Range
6,520.00 - 6,760.00 - 52 Week Range
6,180.00 - 11,700.00 - Volume
35,611 - Avg. Volume
102,266 - Market Cap (intraday)
94.177B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 100.00 (1.49%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Daehan New Pharm Co., Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers human medicine products, such as circulatory and endocrine system drugs; animal medicines; biopharmaceuticals, including biomedicine serums; export medicine which comprises of antibiotics, antineoplastics, and others; health functional food, as well as vitamins; and beauty and medical devices. The company was formerly known as Daehan Shinyak Co., Ltd. and changed its name to Daehan New Pharm Co., Ltd in April 2001. Daehan New Pharm Co., Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.
www.dhnp.co.kr228
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 054670.KQ
View MorePerformance Overview: 054670.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 054670.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 054670.KQ
View MoreValuation Measures
Market Cap
94.18B
Enterprise Value
116.09B
Trailing P/E
6.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.47
Price/Book (mrq)
0.75
Enterprise Value/Revenue
0.57
Enterprise Value/EBITDA
4.79
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.35%
Return on Assets (ttm)
2.09%
Return on Equity (ttm)
-5.45%
Revenue (ttm)
54.48B
Net Income Avi to Common (ttm)
-4B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.72B
Total Debt/Equity (mrq)
58.85%
Levered Free Cash Flow (ttm)
2.47B